ES2185307T3 - Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion. - Google Patents

Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.

Info

Publication number
ES2185307T3
ES2185307T3 ES99901979T ES99901979T ES2185307T3 ES 2185307 T3 ES2185307 T3 ES 2185307T3 ES 99901979 T ES99901979 T ES 99901979T ES 99901979 T ES99901979 T ES 99901979T ES 2185307 T3 ES2185307 T3 ES 2185307T3
Authority
ES
Spain
Prior art keywords
preparation
formula
transferasa
farnesil
piperidinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99901979T
Other languages
English (en)
Inventor
You Seung Shin
Jong Sung Koh
Hyun Il Lee
Jin Ho Lee
Jong Hyun Kim
Hyun Ho Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980002777A external-priority patent/KR100388789B1/ko
Priority claimed from KR1019980028340A external-priority patent/KR100388792B1/ko
Priority claimed from KR10-1998-0032150A external-priority patent/KR100388794B1/ko
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Application granted granted Critical
Publication of ES2185307T3 publication Critical patent/ES2185307T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Un derivado de piperidina representado por la siguiente fórmula (1) **(Fórmula)** en la que A representa hidrógeno, alquilo inferior o **(Fórmula)** en la que B representa CH2, C=O o SO2, y D representa un radical seleccionado del grupo siguiente: **(Fórmulas)** En la definición para el sustituyente D, m representa un número entero de 0 a 3, n representa un número entero de 1 a 3, X representa hidrógeno, fenilo, fenoxi, alquilo C1-C4, alcoxi C1-C4, halógeno, nitro, o amino que está opcionalmente sustituido con bencilo o alquilo C1-C4, R1 y R2 representan independientemente entre sí hidrógeno, alquilo C1-C4, cicloalquilo C3-C6, alquilo C1-C4 sustituido con cicloalquilo C3-C6, arilo o heteroarilo, E representa hidrógeno, fenilo, naftilo o **(Fórmula)** en la que R3 y R4 representan independientemente entre sí hidrógeno, alquilo C1-C4, arilo **(Fórmula)** (en la que Y representa O o S, n¿ representa un número entero de 2 a 4, y R5 representa alquilo C1-C4), G representa un radical seleccionadodel siguiente grupo: **(Fórmulas)** en la que Z representa O, S, SO2 o N-R6 (en la que R6 representa hidrógeno o alquilo C1-C4), R7 y R8 representan independientemente entre sí hidrógeno, alquilo C1-C4, alcoxi C1-C4, halógeno, ciano, hidroxicarbonilo, aminocarbonilo, aminotiocarbonilo, hidroxi, fenilo o fenoxi o una sal farmacéuticamente aceptable del mismo.
ES99901979T 1998-02-02 1999-02-01 Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion. Expired - Lifetime ES2185307T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1019980002777A KR100388789B1 (ko) 1998-02-02 1998-02-02 피롤구조를갖는파네실전이효소억제제및그의제조방법
KR19980002776 1998-02-02
KR1019980028340A KR100388792B1 (ko) 1998-02-02 1998-07-14 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR10-1998-0032150A KR100388794B1 (ko) 1998-08-07 1998-08-07 피페리딘구조를갖는파네실전이효소억제제및그의제조방법

Publications (1)

Publication Number Publication Date
ES2185307T3 true ES2185307T3 (es) 2003-04-16

Family

ID=27483262

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99901979T Expired - Lifetime ES2185307T3 (es) 1998-02-02 1999-02-01 Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.

Country Status (12)

Country Link
US (1) US6436960B1 (es)
EP (1) EP1058683B1 (es)
JP (1) JP3283032B2 (es)
CN (1) CN1158277C (es)
AT (1) ATE229017T1 (es)
AU (1) AU745855B2 (es)
BR (1) BR9908545A (es)
CA (1) CA2320233C (es)
DE (1) DE69904302T2 (es)
ES (1) ES2185307T3 (es)
PT (1) PT1058683E (es)
WO (1) WO1999038862A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100388794B1 (ko) * 1998-08-07 2003-10-10 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR100388792B1 (ko) * 1998-02-02 2003-09-22 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
CN1151148C (zh) * 1999-04-13 2004-05-26 Lgci株式会社 具有吡咯结构的法尼转移酶抑制剂及其制备方法
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
US7035932B1 (en) * 2000-10-27 2006-04-25 Eric Morgan Dowling Federated multiprotocol communication
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR100897642B1 (ko) 2002-12-20 2009-05-14 글락소 그룹 리미티드 신경 장애 치료용 벤즈아제핀 유도체
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
JP4956191B2 (ja) * 2003-10-17 2012-06-20 インサイト コーポレーション マトリックスメタロプロテイナーゼの阻害剤としての置換環状ヒドロキサメート
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
BRPI0716088B8 (pt) 2006-08-28 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
CA2914369C (en) 2013-06-06 2023-02-14 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2863074T3 (es) 2014-06-04 2021-10-08 Biontech Res And Development Inc Anticuerpos monoclonales humanos contra el gangliósido GD2
KR20170087500A (ko) 2014-12-11 2017-07-28 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
AU2016227493B2 (en) 2015-03-03 2022-01-20 Kymab Limited Antibodies, uses & methods
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
US10875920B2 (en) 2015-12-02 2020-12-29 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20200024158A (ko) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
JP7256796B2 (ja) 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
JP2021531007A (ja) 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Ｖｉｓｔａに対する受容体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
CZ229594A3 (en) * 1992-03-25 1995-04-12 Pfizer Peptides, process of their preparation, their use and pharmaceutical compositions based thereon
GB9312806D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
CA2249605A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036900A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0906099A4 (en) * 1996-04-03 2001-02-07 Merck & Co Inc CANCER TREATMENT METHOD
AU715202B2 (en) * 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU716153B2 (en) * 1996-04-03 2000-02-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2193590T3 (es) * 1997-11-28 2003-11-01 Lg Chemical Ltd Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.

Also Published As

Publication number Publication date
CN1158277C (zh) 2004-07-21
AU745855B2 (en) 2002-04-11
EP1058683B1 (en) 2002-12-04
JP3283032B2 (ja) 2002-05-20
US6436960B1 (en) 2002-08-20
WO1999038862A1 (en) 1999-08-05
CN1289331A (zh) 2001-03-28
DE69904302T2 (de) 2003-08-14
BR9908545A (pt) 2001-10-02
CA2320233A1 (en) 1999-08-05
JP2002501918A (ja) 2002-01-22
ATE229017T1 (de) 2002-12-15
EP1058683A1 (en) 2000-12-13
PT1058683E (pt) 2003-04-30
AU2188699A (en) 1999-08-16
DE69904302D1 (de) 2003-01-16
CA2320233C (en) 2004-07-27

Similar Documents

Publication Publication Date Title
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
DE69919397D1 (de) Thrombin-inhibitoren
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
BR9815423A (pt) Composto derivado de imidazol, processo para preparar um derivado de imidazol, e, composição farmacêutica.
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
NO990551L (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
DE69819539D1 (de) Antithrombotische mittel
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
ATE286395T1 (de) Antithrombotische mittel
HN1997000070A (es) Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos
ECSP055804A (es) Composición farmacéutica
UY26971A1 (es) Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos
DE60008430D1 (de) Verbindungen mit antithrombotischer wirkung
ATE277039T1 (de) Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung
BR0314478A (pt) Derivado de 6-metilpiridina, método para sua preparação e composição farmacêutica contendo o mesmo
ATE268768T1 (de) Antithrombosemittel
HUP0302860A2 (hu) Nátrium-hidrogén cserélő 1-típusú inhibitor hatású vegyület új etanolátjai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények